Supercharging clinical trials with data and AI: Realyze’s Aa...

At ASCO 2025, Realyze CEO Aaron Brauser talks transforming clinical trial screening with AI, NLP and real-world data use.

Life beyond lung cancer: Johnson & Johnson’s Breathtaking vi...

Innovation, real-world data, and precision medicine: Pierre ...

Ahead of ASCO 2025, Pierre Fabre charts bold progress in NSCLC with targeted therapies, real-world data, and innovative partnerships

AACR 2025: New modalities and remaining challenges

Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges

The mesenchymal stem cell’s superpower: Hacking the TME

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.